CORT Quote, Financials, Valuation and Earnings

Collegium Pharmaceutical has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 1.36%. Corcept Therapeutics's return on equity of 21.3% beat Collegium Pharmaceutical's return on equity of 19.31%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 86.12%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 38.05%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Corcept Therapeutics has a beta of 0.186, which suggesting that the stock is 81.38% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.635, suggesting its less volatile than the S&P 500 by 36.534%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Corcept Therapeutics's net income of $20.5M is higher than Collegium Pharmaceutical's net income of $2.4M. Notably, Corcept Therapeutics's price-to-earnings ratio is 64.03x while Collegium Pharmaceutical's PE ratio is 24.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.57x versus 1.73x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -907.48%. Corcept Therapeutics's return on equity of 21.3% beat Moderna's return on equity of -29.23%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 86.12%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 85.4%. Given that Corcept Therapeutics has higher upside potential than Moderna, analysts believe Corcept Therapeutics is more attractive than Moderna.

Corcept Therapeutics has a beta of 0.186, which suggesting that the stock is 81.38% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Moderna quarterly revenues of $107M. Corcept Therapeutics's net income of $20.5M is higher than Moderna's net income of -$971M. Notably, Corcept Therapeutics's price-to-earnings ratio is 64.03x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.57x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 21.63%. Corcept Therapeutics's return on equity of 21.3% beat Pfizer's return on equity of 8.72%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 86.12%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.68%. Given that Corcept Therapeutics has higher upside potential than Pfizer, analysts believe Corcept Therapeutics is more attractive than Pfizer.

Corcept Therapeutics has a beta of 0.186, which suggesting that the stock is 81.38% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.08% to investors and pays a quarterly dividend of $0.43 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Corcept Therapeutics's net income of $20.5M is lower than Pfizer's net income of $3B. Notably, Corcept Therapeutics's price-to-earnings ratio is 64.03x while Pfizer's PE ratio is 17.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.57x versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -60.08%. Corcept Therapeutics's return on equity of 21.3% beat Sarepta Therapeutics's return on equity of -20.94%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 86.12%. On the other hand Sarepta Therapeutics has an analysts' consensus of $48.04 which suggests that it could grow by 154.58%. Given that Sarepta Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.186, which suggesting that the stock is 81.38% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Corcept Therapeutics's net income of $20.5M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Corcept Therapeutics's price-to-earnings ratio is 64.03x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.57x versus 0.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.